alexa

GET THE APP

An Update on Minimal Residual Disease(MRD) Assessment in Mantle Cell Lymphoma(MCL): A Mini Review | OMICS International| Abstract

Journal of Oncology Research and Treatment
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Mini Review   
  • J Oncol Res Treat,
  • DOI: 10.4172/aot.s1.1000002

An Update on Minimal Residual Disease(MRD) Assessment in Mantle Cell Lymphoma(MCL): A Mini Review

Dayoung Jung*
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Centre, 1515 Holcombe Blvd, Houston, TX, 77030, USA
*Corresponding Author : Dayoung Jung, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Centre, 1515 Holcombe Blvd, Houston, TX, 77030, USA, Email: [email protected]

Received Date: Mar 25, 2021 / Accepted Date: Apr 08, 2021 / Published Date: Apr 15, 2021

Abstract

The field of minimal residual disease in most B-cell malignancies is critical. This is especially true for mantle cell lymphoma, a rare but aggressive subtype of non-Hodgkin’s lymphoma. A recent review of available minimal residual disease assessment methods has shown promising results in mantle cell lymphoma, specifically in the advancement of circulating tumour DNA-based liquid biopsy methods. While there are various minimal residual disease markers in mantle cell lymphoma, finding the best suitable marker remains a problem yet to be solved. Because minimal residual disease monitoring is not yet validated in clinical trials, seeing studies that include such an assessment has become valuable in determining if it can accurately aid in identifying future prognostics and outcomes of a chosen therapy method. By using next generation sequencing methods, liquid biopsy is able to utilize various sample types, like circulating tumour cells, cell-free DNA, circulating tumour DNA, and etc., from a drop of blood to assess the molecular landscape of the tumour in a non-invasive manner. More recent updates on the basic methods, available markers, and liquid biopsy assessments in mantle cell lymphoma are described in this mini-review.

Keywords: Non-Hodgkin lymphoma; Minimal Residual Disease (MRD); Mantle cell lymphoma; Lymphocytic leukaemia

Citation: Jung D (2021) An Update on Minimal Residual Disease (MRD) Assessment in Mantle Cell Lymphoma (MCL): A Mini Review. J Oncol Res Treat S1:002. Doi: 10.4172/aot.s1.1000002

Copyright: © 2021 Jung D. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Article Usage
  • Total views: 353
  • [From(publication date): 0-0 - Dec 06, 2021]
  • Breakdown by view type
  • HTML page views: 129
  • PDF downloads: 224
Top